Prognostic implications of different clinical profiles in hypertrophic cardiomyopathy.


Journal

Minerva cardiology and angiology
ISSN: 2724-5772
Titre abrégé: Minerva Cardiol Angiol
Pays: Italy
ID NLM: 101776555

Informations de publication

Date de publication:
Apr 2022
Historique:
pubmed: 30 10 2021
medline: 14 4 2022
entrez: 29 10 2021
Statut: ppublish

Résumé

Hypertrophic cardiomyopathy (HCM) is a myocardial genetic disease relatively common in the general population with heterogenous clinical presentation, natural history and prognosis. About 60% of HCM patients have a stable clinical course, while others may experience a variety of HCM-related complications which follows relatively independent pathways, and that can be distinguished in different subgroups. These subgroups are represented by patients with left ventricular outflow tract obstruction; patients with end-stage disease and reduced or preserved systolic function; patients with apical hypertrophy; patients with apical aneurysm; patients with atrial fibrillation, patients at high risk of sudden death and patients with preclinical HCM. The purpose of this review was to describe each of these clinical profiles with its prognostic implications.

Identifiants

pubmed: 34713676
pii: S2724-5683.21.05752-5
doi: 10.23736/S2724-5683.21.05752-5
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

189-206

Auteurs

Domitilla Russo (D)

Unit of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Matteo Sclafani (M)

Unit of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Giacomo Tini (G)

Unit of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

M Beatrice Musumeci (MB)

Unit of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Luca Arcari (L)

Unit of Cardiology, Madre Giuseppina Vannini Hospital, Rome, Italy.

Luca R Limite (LR)

Unit of Arrhythmia and Electrophysiology Laboratories, Department of Cardiology and Cardiothoracic Surgery, San Raffaele Hospital, Milan, Italy.

Pietro Francia (P)

Unit of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Camillo Autore (C)

Unit of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University, Rome, Italy - camillo.autore@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH